Expertise in
1
conditions

Yong C. Lee

Jeonju, KR 
Expertise in
1
conditions
Jeonju, KR 

Overview

Yong Lee practices practicing medicine in Jeonju, Republic of Korea.

Lee is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Allergic Bronchopulmonary Aspergillosis, Epithelial-Myoepithelial Carcinoma, Diffuse Panbronchiolitis, and Pneumonia.

They are actively involved in clinical research, co-authoring 94 peer reviewed articles and participating in 2 clinical trials.

Locations

Jeonju, Republic of Korea
Other Locations
Seoul, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: August 21, 2026
Intervention Type: Drug, Biological
Study Drug: Mepolizumab
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Biological
Study Drug: RSVPreF3
Study Phase: Phase 3
View 1 Less Clinical Trial

94 Total Publications

Non-invasive aspergillosis following COVID-19 exacerbates the severity of SARS-CoV-2 infection.
Non-invasive aspergillosis following COVID-19 exacerbates the severity of SARS-CoV-2 infection.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: May 01, 2026

Frequently Asked Questions about Yong C. Lee

Is Yong C. Lee a top-rated expert for Allergic Bronchopulmonary Aspergillosis?

MediFind is an objective health platform that identifies experts based on real-world data. Yong C. Lee is classified as an Advanced expert for Allergic Bronchopulmonary Aspergillosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Yong C. Lee participate in research or clinical trials?

Yes. Yong C. Lee has published 94 articles and abstracts on conditions like Allergic Bronchopulmonary Aspergillosis. You can view a list of Yong C. Lee's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Lee's expertise for a condition
ConditionClose
      View All 25 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile